Podcasts about AbbVie

In this episode, I talk with Ning Leng, Ph.D., Director II, Data and AI Acceleration Group, Data & Statistical Sciences at AbbVie, about the growing role of the R Consortium in the pharmaceutical industry. Ning brings extensive experience in statistics, computational genomics, open-source technology, and the adoption of R across the pharmaceutical industry. Before joining AbbVie, she spent 10 years at Roche Genentech, where she helped drive the adoption of R, cloud technologies, Git, and Shiny. We discuss how the R Consortium creates a platform for statisticians, programmers, pharmaceutical companies, and regulators to collaborate on practical challenges—and how that collaboration is changing the way we approach regulatory submissions.

In this Live Greatly 2 Minutes of Motivation episode, Kristel Bauer shares why becoming a better leader starts with self-awareness. Discover the importance of taking ownership of how you show up, getting curious about your biases and habitual reactions, and building the awareness to respond more intentionally. Tune in for a quick mindset shift to help you grow as a leader and navigate challenges with greater confidence and intention. If you're looking to support your team with sustainable high performance, resilience, and clear decision-making in high-pressure environments, Kristel brings these strategies to organizations through engaging keynote experiences. Learn more: www.livegreatly.co  Kristel delivers high-impact keynotes on: Peak performance Burnout prevention Leadership development Workplace well-being Sustainable success

In this episode of Mind the Meds, host Erica Marini, PharmD, MS, BCPS, welcomes Jenelle Hall Montgomery, PharmD, BCACP, CPP, a clinical pharmacist practitioner with Duke Neurological Disorders Clinic at Duke University Hospital, to discuss highlights from the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting in Charlotte, North Carolina, where Montgomery was recognized as a Giant of Multiple Sclerosis. Before the CMSC discussion, Marini runs through a roundup of recent neurology news, including approval of at-home initiation dosing for lecanemab-irmb (Leqembi; Eisai, Biogen), fast track designation for remlifanserin (Acadia Pharmaceuticals) in Alzheimer disease psychosis, approval of the oral PCSK9 inhibitor enlicitide (Lipfendra; Merck), and phase 3 data on tavapadon (AbbVie) for Parkinson disease showing a lower rate of impulse control disorders than traditional dopamine agonists.The pharmacists then turn to CMSC sessions on off-label and evolving areas of MS care. They discuss growing interest in neurofilament light chain as a biomarker for tracking subclinical disease progression over time, along with the ongoing debate over when it is safe to discontinue disease-modifying therapy (DMT) in older, stable patients. Both note their practices generally begin this conversation around 60 to 65 years of age, factoring in radiographic and clinical stability over the preceding decade, and describe strategies such as tapering dosing frequency or switching to lower-efficacy agents rather than abrupt discontinuation.The conversation closes with an update on family planning in MS, where new data presented at CMSC reinforce the safety of anti-CD20 therapies during pregnancy and breastfeeding. Montgomery and Marini review a 10-year dataset of about 5000 pregnancies on ocrelizumab (Ocrevus; Genentech), a large safety analysis of ofatumumab (Kesimpta; Novartis Pharmaceuticals) showing no increase in birth malformations, and early transfer-into-breastmilk data on ublituximab (Briumvi; TG Therapeutics). They also touch on the limited but growing evidence for GLP-1 receptor agonists in patients with MS, noting no known drug interactions with DMTs and possible indirect benefit through weight-related disease modulation, though neither pharmacist currently prescribes GLP-1s for an MS indication.Key Takeaways:1. Neurofilament light chain is emerging as a useful, though not yet mainstream, biomarker in MS. Rather than a single value, tracking neurofilament light chain over time alongside clinical status may help identify subclinical disease progression, particularly in patients without clear relapses.2. DMT discontinuation in older, stable patients remains individualized, with most practices starting the conversation around 60 to 65 years of age. Clinicians weigh 10-year clinical and radiographic stability, and some patients opt for a gradual step-down in dosing frequency or a switch to a lower-efficacy agent rather than outright discontinuation.3. New pregnancy and breastfeeding safety data continue to support anti-CD20 therapies as a preferred family planning strategy in MS. A 10-year, 5000-pregnancy dataset on ocrelizumab, reassuring malformation data on ofatumumab, and early breastmilk transfer data on ublituximab are strengthening patient counseling conversations around conception, pregnancy, and postpartum DMT resumption.

The owner of NBC Tower plans to convert part of the building to hundreds of apartments. Crain's commercial real estate reporter Danny Ecker discusses with host Amy Guth. Plus: Johnson loses budget director days after CFO exit, Illinois joins 24 other states in suit challenging Trump's latest tariffs, AbbVie seeks at least $8 billion in debt to fund Apogee deal and McDonald's replaces U.S. president in slow-growth shakeup. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into recent transformative events that are shaping this dynamic industry, from strategic mergers to groundbreaking drug approvals. Starting with the merger between Supernus Pharmaceuticals and Indivior Pharmaceuticals, this all-stock deal valued at $2.2 billion is set to create a powerhouse focused on central nervous system (CNS) disorders. By combining their resources, the new entity is expected to enhance its capabilities in neurological disorders with a robust portfolio of approved drugs. This merger allows the companies to leverage economies of scale, optimize research and development, and expand their market presence, offering promising prospects for advancements in treating CNS-related conditions. In regulatory news, Novartis has secured FDA approval for an expanded indication of Pluvicto (lutetium vipivotide tetraxetan), a radioligand therapy originally approved for PSMA-positive metastatic castration-resistant prostate cancer. This therapy can now be used for metastatic hormone-sensitive prostate cancer, marking a significant step forward in prostate cancer treatment. By targeting prostate-specific membrane antigen (PSMA) with precision, Pluvicto offers the potential for improved patient outcomes and highlights the growing role of radioligand therapies in oncology. Globally, Pharmamar's Zepzelca (lurbinectedin) has been approved in Canada, Qatar, and South Korea as a first-line maintenance therapy for extensive-stage small cell lung cancer. This approval signifies a potential shift in how aggressive cancer types are treated, particularly when combined with PD-L1 inhibitors, opening new avenues for effective combination therapies. Industry partnerships continue to drive innovation, as seen with Fujifilm and Taiho Pharmaceutical's collaboration to develop next-generation antibody-drug conjugate (ADC) manufacturing technologies using the Aralinq platform. With ADCs becoming increasingly pivotal in targeted cancer therapies due to their precision in delivering cytotoxic drugs to tumor cells, advancements in manufacturing could significantly enhance production capabilities and therapeutic efficacy. Financial dynamics within the industry remain robust. AbbVie has raised its 2026 revenue forecast to $67.6 billion, citing strong performances from its immunology drugs Skyrizi and Rinvoq. These therapies have shown substantial success in treating autoimmune conditions, reflecting their impact on AbbVie's financial health and reinforcing confidence in their commercial viability. On the clinical trial front, Ratio Therapeutics has successfully closed a $70 million Series C funding round to support its radiotherapeutics pipeline and initiate the ATLAS trial. This infusion of funds underscores the continued interest and investment in radiopharmaceuticals with promising applications in oncology. The landscape of mergers and acquisitions remains active as AstraZeneca and Bristol Myers Squibb reportedly engage in early-stage merger discussions. Such a merger could create an oncology giant valued at approximately $400 billion, potentially reshaping competitive dynamics and accelerating innovation across therapeutic areas. Regulatory changes are also underway with HRSA advancing a revised 340B rebate model pilot program despite hospital opposition. The implications for healthcare providers are significant as this could affect operational efficiencies and financial strategies within participating entities. Overall, these developments reflect ongoing trends toward industry consolidation and strategic partnerships that foster innovation in drug manufacturing technologies. Regulatory approvals continue to advance precision medicine through targeted therapies, showcasing the sector's dynamic nature as it addresses unmet medical needs while navigating complex regulatory environments. Meanwhile, Sandoz's settlement of nearly $500 million for antitrust claims in the U.S. highlights ongoing scrutiny of industry competition practices. This settlement signals potential shifts in market dynamics as companies seek to resolve legal challenges while maintaining operational integrity. Cybersecurity has emerged as a critical concern following Amgen's reported breach compromising sensitive patient data. This incident amplifies the need for enhanced data protection measures to safeguard information integral to patient trust and competitive integrity. In leadership news, BioNTech has appointed Guido Oelkers as CEO amid its continued innovation in mRNA technology post-COVID-19. This strategic move underscores BioNTech's commitment to leadership capable of navigating advances in mRNA therapeutics. Lastly, Novo Nordisk faced setbacks with its investigational therapy ziltivekimab failing a phase 3 trial targeting inflammatory pathways for cardiovascular outcomes. Despite such challenges, these high-stakes trials highlight both risks and opportunities inherent in pharmaceutical innovation. As we reflect on these stories, it's clear that scientific advancements, regulatory developments, and strategic business moves continue to shape the trajectory of the pharmaceutical and biotech sectors. These efforts promise significant implications for future drug development and patient care as companies strive to harness breakthroughs while adapting to evolving industry landscapes.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent weeks have been a whirlwind of activity in the pharmaceutical and biotech sectors, showcasing significant strides in scientific breakthroughs, regulatory advancements, and strategic industry maneuvers. Replimune's Vusolimogene Oderparepvec has emerged as a beacon of hope in the fight against advanced melanoma. This gene therapy, utilizing an oncolytic virus, has recently received a positive nod from an advisory committee for its Phase 1/2 trial. When combined with PD-1 checkpoint inhibitors, it holds promise for enhancing immune responses against tumors—a critical development in cancer treatment that may redefine therapeutic strategies. This advancement follows two prior FDA rejections, underscoring the multifaceted evaluation process drugs undergo before approval and demonstrating that perseverance can eventually lead to success. Meanwhile, AstraZeneca and Daiichi Sankyo have achieved a milestone with the European Union's approval of Datopotamab Deruxtecan for treating unresectable or metastatic triple-negative breast cancer (TNBC). As an antibody-drug conjugate targeting the Trop-2 protein, it offers new hope to TNBC patients who often have limited options. This approval underscores the potential of antibody-drug conjugates in oncology, supported by promising Phase 3 trial data. Regeneron Pharmaceuticals is enjoying notable revenue growth thanks to Dupixent, a monoclonal antibody addressing autoimmune and respiratory diseases. Such financial success underscores the expanding role of biologics in tackling chronic illnesses, reflecting a broader industry trend towards biologically-based treatments. In business news, Pharmanovia's licensing deal with Impact Therapeutics for Senaparib signifies strategic expansion in oncology therapeutics. Similarly, Kaigene's agreement with Taisho Pharmaceutical highlights ongoing interest in autoimmune therapies, illustrating how companies are leveraging partnerships to broaden their therapeutic horizons. Pfizer is on the brink of expanding its label for Ritlecitinib (Litfulo), a JAK3 inhibitor that showed positive results in Phase 3 trials for nonsegmental vitiligo. By targeting autoimmune pathways, this small molecule could offer new hope to vitiligo patients seeking effective treatments. Litfulo is advancing through regulatory stages following successful trials, poised to provide an oral alternative for non-segmental vitiligo—a potential game-changer that could improve patient compliance and expand treatment options beyond Incyte's Opzelura. However, not all news is positive. Novo Nordisk faced disappointment when its Ziltivekimab failed a Phase 3 trial for atherosclerotic cardiovascular disease with chronic kidney disease. Despite this setback, Novo Nordisk remains optimistic about ongoing trials Artemis and Hermes as potential lifelines for their CKD program. Success could diversify their portfolio and introduce novel therapeutic options for CKD patients. Additionally, financial hurdles surfaced as Daiichi Sankyo saw an 11% share drop due to an accounting error, and Alnylam Pharmaceuticals' market value took a hit following a lowered revenue forecast for its TTR drug. On a global scale, the Trump administration has allocated $600 million to GAVI for childhood immunizations worldwide. This funding reversal emphasizes ongoing efforts to ensure vaccine accessibility across the globe—an essential component of public health initiatives. The dynamic nature of these developments reflects both the potential and challenges within the pharmaceutical landscape. The promising avenues presented by gene therapy, antibody-drug conjugates, and JAK inhibitors are tempered by clinical setbacks and financial volatility, underscoring the rigorous demands faced by industry stakeholders. In other industry news, AbbVie's Skyrizi continues to thrive despite increasing competition in the psoriasis market. With sales reaching $5.55 billion in Q2 2026, Skyrizi demonstrates the sustained demand for innovative biologics that enhance treatment efficacy and safety profiles. Karyopharm Therapeutics remains committed to its XPO1 inhibitor Xpovio despite setbacks in other indications like endometrial cancer. Their focus on myelofibrosis illustrates a strategic pivot towards hematologic malignancies where unmet needs persist. Oral GLP-1 receptor agonists are gaining ground as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie for dominance in weight management solutions. These oral formulations promise increased accessibility over traditional injectables. Regulatory arenas continue to evolve with AbbVie's Rinvoq gaining European clearance for alopecia and vitiligo. Such approvals highlight regulatory bodies' critical role in expanding market access across diverse therapeutic areas. Strategic partnerships also abound as WellSpan Health collaborates with Hippocratic AI to integrate artificial intelligence into healthcare solutions—a growing trend aimed at enhancing clinical decision-making capabilities. Meanwhile, Apnimed's $192 million IPO success indicates strong investor confidence in novel therapeutics like its sleep apnea treatment—a reflection of biopharma's financing dynamics where targeted therapies draw significant interest. Overall, these updates paint a vivid picture of an industry characterized by relentless innovation through scientific research, strategic alliances, and regulatory progress—all aimed at improving patient outcomes amidst evolving market demands. The industry's focus on breakthrough technologies continues to shape global health initiatives by offering new opportunities for patient care across various conditions. As companies navigate this dynamic environment marked by both promise and challenge—their ability to innovate scientifically while engaging strategically with regulators will be crucial to bringing novel therapies effectively into clinical practice where they can make meaningful impacts on patients' lives worldwide.Support the show

On this re-release episode of the Live Greatly 2 Minutes of Motivation podcast, Kristel Bauer explores a common belief that may be limiting your success: the idea that meaningful results have to come from hard, complicated work. Discover why simplifying your approach, focusing on small, intentional habits, and taking consistent action can often lead to greater long-term success. Tune in for a quick mindset shift that can help you work smarter, not just harder. If you're looking to support your team with sustainable high performance, resilience, and clear decision-making in high-pressure environments, Kristel brings these strategies to organizations through engaging keynote experiences. Learn more: www.livegreatly.co  Kristel delivers high-impact keynotes on: Peak performance Burnout prevention Leadership development Workplace well-being Sustainable success

The US and Israel are considering a land blockade of Iran to increase economic pressure, senior Israeli sources told The Telegraph. The plan could involve urging neighbouring countries and regional partners to restrict border crossings and trade.Iran's IRGC said two offending tankers were hit and stopped, and four offending tankers quickly changed course. Additionally, the IRGC said the Strait of Hormuz is closed, and any transit and movement will be possible only with the coordination of the IRGC Navy. BoJ kept rates unchanged at 1.00%, as expected, through an 8-1 vote, with board member Takata the dissenter who proposed a 25bps rate hike. Little move seen in Japanese assets following the announcement and Governor Ueda press conference. US equity futures are firmer, with Amazon surging pre-market (+12%) after reporting faster AWS growth.Fixed income benchmarks are mixed and way off best levels as energy prices rebound following recent reporting of a land blockade and hit tankers (Brent +0.3%).Looking ahead, highlights include Canadian GDP (May), US University of Michigan Final (Jul). Speakers include BoE's Pill, Fed's Hammack, Logan & Kashkari. Earnings from AbbVie & Chevron. Scope Ratings update on Switzerland.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

US Treasury Secretary Bessent said the yen has substantially overshot equilibrium and the US views excess yen volatility as unhealthy, while he added that the yen is very undervalued and that Japan may have intervened in currency markets on Thursday.Nikkei sources said Japan's government and BoJ intervened in the FX market yesterday by buying yen and selling dollars, while desks conducted rate checks.BoJ kept rates unchanged at 1.00%, as expected, through an 8-1 vote, with board member Takata the dissenter who proposed a 25bps rate hike; little move in Japanese assets on the announcement.After-hours US earnings saw Amazon (AMZN) rise almost 10% whilst Apple (AAPL) fell over 6%.APAC stocks were mostly higher following the tech-inspired momentum stateside; European equity futures indicate a positive cash market open with Euro Stoxx 50 futures up 0.8%.Looking ahead, highlights include French/Italian/EU Inflation Flash (Jul), German Unemployment Rate (Jul), Canadian GDP (May), US University of Michigan Final (Jul). Speakers include BoJ Governor Ueda, BoE's Pill, Fed's Hammack, Logan & Kashkari. Earnings from AbbVie, Chevron, Credit Agricole & NatWest. Scope Ratings update on Switzerland rating.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Biogen has made a significant acquisition by purchasing Apellis Pharmaceuticals, a move expected to boost its 2026 revenue guidance with promising growth prospects. This strategic acquisition, along with strong sales from new drugs, enhances Biogen's position in the competitive market for neurological disorders. By integrating Apellis' offerings, Biogen is poised to strengthen its portfolio, particularly in areas of unmet medical need. On the regulatory front, AbbVie has achieved a milestone with its drug Rinvoq (upadacitinib), which has received dual approvals from the European Union for treating non-segmental vitiligo and severe alopecia areata. These approvals were based on successful Phase 3 data, underscoring Rinvoq's efficacy as a JAK inhibitor in tackling autoimmune conditions. This development not only highlights AbbVie's commitment to expanding its therapeutic portfolio but also positions upadacitinib as a potential mainstay treatment for dermatological autoimmune diseases. AstraZeneca Pharma India has secured approval from the Central Drugs Standard Control Organization for Enhertu (trastuzumab deruxtecan) in the neoadjuvant setting for HER2-positive early breast cancer. This approval marks a significant advancement in personalized cancer therapy, offering new hope for patients with this aggressive form of breast cancer. In terms of industry collaborations, the landscape is witnessing numerous partnerships and strategic alliances that are driving innovation forward. Skyverna Therapeutics and ElevateBio have entered a five-year clinical and commercial supply agreement for autoimmune CAR-T therapy, reflecting the growing interest in cell therapies for rare diseases. Meanwhile, Vertex Pharmaceuticals and AbCellera have joined forces to accelerate drug discovery in autoimmune T-cell engagement, supported by a $28 million upfront investment. These collaborations emphasize the importance of combining expertise and resources to advance complex therapeutic solutions. The integration of artificial intelligence in drug development continues to gain momentum. Evinova and Merck KGaA's strategic collaboration aims to leverage AI and machine learning to enhance clinical trials' efficiency, potentially ushering in a new era of precision medicine. Such partnerships highlight the transformative potential of AI in streamlining research and development processes. In funding news, Core Biomedicine has secured $21 million in Series A financing to advance its precision oncology therapeutics. Enlivex's substantial $400 million private placement aims at advancing prediction markets treasury and Allocetra immunotherapy, further accentuating the focus on personalized medicine targeting specific cancer pathways. Clinical trials have also delivered promising results. ProMIS Neurosciences reported positive interim safety and biomarker data from its Phase 1b study of PMN310 for Alzheimer's disease. This monoclonal antibody targets amyloid-beta oligomers implicated in Alzheimer's pathology, offering hope for patients with this debilitating disorder. Mergers and acquisitions remain active, exemplified by Caldera Therapeutics' reverse merger with Synlogic alongside $278 million in financing to advance its bispecific antibody for inflammatory bowel disease. This move reflects a broader trend toward consolidating resources to tackle complex autoimmune conditions. Eli Lilly's ascent to the top of Norstella's pipeline-to-patient productivity index is noteworthy, driven by successful launch strategies and rapid development cycles. This achievement underscores Eli Lilly's effective alignment of R&D efforts with market needs, particularly in areas such as GLP-1 receptor agonists that have transformed diabetes care. Teva Pharmaceuticals is demonstrating resilience through its innovative medicines portfolio amidst declining generic sales. The unexpected surge in Ajovy sales highlights Teva's pivot toward high-value branded drugs amidst competitive pressures. Novo Nordisk faces legal challenges as it navigates allegations regarding Cagrisema's Phase 3 study protocol changes. Legal scrutiny around transparency in clinical trial disclosures continues to highlight the importance of ethical practices and investor trust. Collectively, these developments illustrate a vibrant yet challenging environment where scientific advancements in immunotherapy and targeted treatments intersect with strategic business alignments focused on sustainable growth. As these trends unfold, they promise more effective treatments for complex diseases while companies adapt to an evolving market environment demanding agility and foresight. As always, stay tuned to Pharma Daily for more insights into how these transformations continue to shape the future trajectory of drug development and healthcare delivery globally.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a wealth of significant advancements and strategic moves shaping the industry landscape. AstraZeneca is making waves with its steadfast commitment to reaching an $80 billion revenue target by 2030. This ambitious goal is underpinned by strong sales in oncology and rare disease treatments, despite some setbacks with underperforming drugs like Ultomiris. The company's confidence is further reflected in its robust internal pipeline of antibody-drug conjugates (ADCs), even after discontinuing two candidates that fell short in clinical trials. This move highlights an industry-wide focus on high-potential therapeutic areas, underscoring the critical role of sustained innovation in preserving market leadership. In leadership news, Sarepta Therapeutics has appointed Michael Severino as CEO, succeeding Doug Ingram. Severino's extensive experience from AbbVie and Tessera signals a strategic shift for Sarepta, especially as it hones its focus on therapies for Duchenne Muscular Dystrophy. Leadership transitions like this can significantly impact a company's strategic direction, potentially steering it toward new therapeutic breakthroughs. On the regulatory front, Otsuka's Simtriyo has received FDA approval, marking it as a first-in-class norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) for ADHD. This approval is a major leap forward in central nervous system therapeutics, offering a non-stimulant option that could become a blockbuster drug in this underserved market. Such advancements highlight the persistent need for innovative treatments in CNS disorders. Similarly, Outlook Therapeutics has achieved FDA approval for Lytenava, a reformulated version of Roche's Avastin for wet age-related macular degeneration (AMD). This victory, following three prior rejections, exemplifies the challenges and opportunities inherent in drug reformulation and regulatory perseverance. Corporate acquisitions continue to shape industry dynamics. Argenx's acquisition of Forte Biosciences for $2.2 billion exemplifies strategic investments aimed at expanding therapeutic portfolios. Forte's promising Phase 2-stage vitiligo drug acquisition underscores the industry's shift towards biologics in managing complex autoimmune disorders. Amgen's recent layoff of approximately 40 employees aligns with broader trends of operational optimization amidst organizational restructuring. Such workforce adjustments often reflect shifts in business strategy or responses to evolving market conditions. In clinical development news, InnoCare Pharma has announced successful Phase 3 results for its oral TYK2 inhibitor Fadeucravacitinib in treating moderate-to-severe plaque psoriasis. This achievement underscores the potential of targeted therapies in addressing autoimmune conditions by modulating specific signaling pathways. The FDA's approval of Freenome's SimpleScreen CRC blood test marks a significant advancement in non-invasive diagnostic tools for colorectal cancer screening. Such innovations could dramatically impact early cancer detection and improve patient outcomes. Meanwhile, emerging insights into CAR-T therapy have identified genetic markers linked to toxicity risks in Yescarta patients. These findings can guide future CAR-T product development towards enhanced safety profiles, offering pathways for engineering safer therapies by identifying patients at higher risk for adverse effects. Finally, the partnership between Salesforce and Veterans Affairs aims to integrate AI into healthcare workflows, illustrating the increasing role of digital transformation in enhancing healthcare delivery and operational efficiency. These developments highlight the ongoing evolution towards more personalized and efficient healthcare solutions within the pharmaceutical and biotech sectors. As companies navigate complex regulatory landscapes, pursue innovative therapies, and adapt to dynamic market demands, their efforts are poised to advance patient care standards and drive future growth within these critical industries. The implications for patient care are profound, as new treatments offer hope for conditions that have long eluded effective intervention. Stay tuned with Pharma Daily as we continue to bring you the latest updates from this rapidly evolving field.Support the show

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YFB865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Evolving Strategies in Testing and Treatment of MET-Altered NSCLC: Clinical Complexities and Real-World Practicalities In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AbbVie.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YFB865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Evolving Strategies in Testing and Treatment of MET-Altered NSCLC: Clinical Complexities and Real-World Practicalities In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AbbVie.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YFB865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Evolving Strategies in Testing and Treatment of MET-Altered NSCLC: Clinical Complexities and Real-World Practicalities In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AbbVie.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YFB865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Evolving Strategies in Testing and Treatment of MET-Altered NSCLC: Clinical Complexities and Real-World Practicalities In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AbbVie.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YFB865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Evolving Strategies in Testing and Treatment of MET-Altered NSCLC: Clinical Complexities and Real-World Practicalities In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AbbVie.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YFB865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Evolving Strategies in Testing and Treatment of MET-Altered NSCLC: Clinical Complexities and Real-World Practicalities In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AbbVie.Disclosure information is available at the beginning of the video presentation.

On this re-release episode of the Live Greatly 2 Minutes of Motivation podcast, Kristel Bauer shares 3  tips to help you receive feedback more effectively so you can grow personally and professionally. Learning how to accept constructive feedback without becoming defensive can strengthen your leadership skills, improve communication, and support long-term career success.  If you're looking to support your team with sustainable high performance, resilience, and clear decision-making in high-pressure environments, Kristel brings these strategies to organizations through engaging keynote experiences. Learn more: www.livegreatly.co  Kristel delivers high-impact keynotes on: Peak performance Burnout prevention Leadership development Workplace well-being Sustainable success

In this episode, hosts Sameer Berry, MD, and William Chey, MD, speak with Sarah Enslin, PA-C, Vivek Kaul, MD, and Amy Stewart, CRNP, about the benefits of introducing advanced practice providers in practice and how to help them succeed. ·       How can advanced practice providers, or APPs, help overcome access barriers in gastroenterology? 6:54 ·       How can we effectively onboard APPs? 10:24 ·       Is ACG's APP Academy for Clinical Excellence accounting for the fact that different specialties and practices have different requirements? 18:21 ·       What models have worked well for deploying APPs into GI practices? 24:32 ·       What strategies are most effective for APP retention? 29:07 ·       How can we improve professional development for APPs? 42:14 We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro, @sameerkberry and @umfoodoc.  Berry and Chey report no financial disclosures. Stewart reports financial relationships with AbbVie, Ardelyx, Celltrion, Cristcot, Eli Lilly & Co, Exact Sciences, Genentech, Johnson & Johnson, Merck, Mindset Health (Nerva), Nestle Health Science, Pfizer, Phathom Pharmaceuticals, Prometheus Laboratories, Regeneron, Salix Pharmaceuticals, Sanofi and Takeda Pharmaceuticals. Healio could not confirm relevant financial disclosures for Enslin and Kaul at the time of publication.

Host: Rasha Al-Lamee Guests: Christina Magnussen Want to watch that extended interview on risk factors and longevity in women and in men, go to: https://esc365.escardio.org/event/2559?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/2559   Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Rasha Al-Lamee has declared to have potential conflicts of interest to report:speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir, Astrazeneca. Consulting Fees: Menarini pharmaceuticals, Abbott, Philips, Shockwave, Elixir, IsomAB, VahatiCor, SpectraWave, AstraZeneca, Cathworks, Janssen Pharmaceuticals. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Christina Magnussen has declared to have potential conflicts of interest to report: speaker fees from Novartis, Novo Nordisk, Bayer, Boehringer Ingelheim and Edwards. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Risk factors and longevity in women and in men  Mythbusters: Smartphone interference with pacemakers, ICDs Host: Rasha Al-Lamee Guests: JP Carpenter, Christina Magnussen Want to watch that episode? Go to: https://esc365.escardio.org/event/2559 Want to watch that extended interview on risk factors and longevity in women and in men, go to: https://esc365.escardio.org/event/2559?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Rasha Al-Lamee has declared to have potential conflicts of interest to report:speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir, Astrazeneca. Consulting Fees: Menarini pharmaceuticals, Abbott, Philips, Shockwave, Elixir, IsomAB, VahatiCor, SpectraWave, AstraZeneca, Cathworks, Janssen Pharmaceuticals. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Christina Magnussen has declared to have potential conflicts of interest to report: speaker fees from Novartiq, Novo Nordisk, Bayer, Boehringer Ingelheim and Edwards. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Chalene Johnson breaks down the Instagram AI feature that had the internet in a panic last week, why deepfake scammers are now stealing real videos and subtly altering someone's voice and appearance to make fake endorsements look real, and what to watch for so you don't get fooled. She also shares a new survey showing that a large percentage of perimenopausal and menopausal women have no idea what stage of reproduction they're in, and explains why she's been getting stronger and leaner using a hormone marker called sex hormone binding globulin, or SHBG, something most doctors won't test unless you specifically request it. She recommends Midi Health for anyone who wants a full hormone panel done right. Chalene gives a quick update on the Blake Lively and Justin Baldoni legal saga, including the ongoing dispute over $8 million in legal fees, then moves into the difference between Botox, Juvederm, and Sculptra, her own experience with Sculptra after her facelift, and a new lawsuit against Juvederm maker AbbVie. She closes with a passionate defense of Madonna following her World Cup halftime performance, walking through Madonna's decades of reinvention, her physical training history, and why Chalene believes the ageism criticism aimed at her is completely out of line. Topics discussed: Instagram, AI deepfakes, perimenopause, menopause, sex hormone binding globulin, Midi Health, Blake Lively, Justin Baldoni, AB 933, Botox, Juvederm, AbbVie, Sculptra, Beauty Broker, Madonna, World Cup Go Beyond The Podcast Join Chalene on her private podcast

O'Hare airport's passenger numbers rebounded last year, but its rivals also made gains. Crain's airlines reporter John Pletz discusses with host Amy Guth. Plus: Feds subpoena Chicago law firms in Trump's fight with ABA, Shore Capital unloads veterinary real estate portfolio for $268 million, AbbVie's Allergan gets European nod for its Botox-lite treatment and more lawyers join Resilience legal scrum, delaying settlement and West Suburban reopening. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

How can you strengthen your attention and perform at your best under pressure? In this episode of 2 Minutes of Motivation, Kristel Bauer shares three simple, science-backed strategies to help you improve your focus when it matters most. Whether you're preparing for a presentation, leading a meeting, or navigating a high-pressure moment, these actionable insights can help you stay focused on what matters most. Key Takeaways: How to recognize what's pulling your attention away Simple ways to redirect your focus in high-pressure moments Healthy habits that can strengthen your attention and resilience over time If you enjoy this episode, be sure to follow the Live Greatly podcast for more short mindset boosts and conversations with world-class leaders, authors, and experts focused on leadership, resilience, well-being, and sustainable high performance. If you're looking to support your team with sustainable high performance, resilience, and clear decision-making in high-pressure environments, Kristel brings these strategies to organizations through engaging keynote experiences. Learn more: www.livegreatly.co  Hosted by Kristel Bauer, keynote speaker, author, and performance expert. Kristel delivers high-impact keynotes on: Peak performance Burnout prevention Leadership development Workplace well-being Sustainable success

Imagine a dark warehouse. Racks and racks of devices with wires, tubes, and electronics sticking out. The next AI data center? No. This is Lila Sciences‘ dream for the future of science. A dark warehouse full of AI-guided robotics and lab equipment, cranking out new experiments 24/7, building toward a scientific superintelligence.Their automated lab is almost hypnotizing to watch. They have floating plates zipping around on Wall-E-esque tracks, used vision-language models to control Windows 95 boxes, and created the world's largest collection of voided warranties. In the process they've built a massive library of scientific reasoning tokens. Over 10 trillion of them, all experimentally validated.No warranties were voided in the making of this videoTo say Lila is ambitious is an understatement. Their goal is a scientific superintelligence wired directly into the wet lab. They are all in on the bitter lesson, and the thesis follows from it: a lab is an infinite token generator. Produce data at scale, and the synergies give you a general reasoner that can tackle any scientific problem. They are committing hard. Biology, chemistry, drug discovery, and materials science, all at the same time. Time will tell if it works, but it is an exciting hypothesis.In our latest episode we sat down with Lila's very own Andy Beam (CTO) and Rafa Gómez-Bombarelli (CSO, physical sciences) and went on a journey through the possibilities of AI-run science, almost as wide-ranging as Lila's goals.Did we mention they do both materials science and biology? In the same AI science factory? Same time, same lab, same AI. Finally a guest who can settle a long-running debate we've had amongst ourselves: is biology or materials science harder?Watch to find out!We discuss:* The internet is spent, science is next. Why Lila thinks the scientific method is the last untapped internet-scale dataset, and why they treat RL as a data generation mechanism with nature as the verifier.* The lab as a data center. Instruments as nodes on a graph, a magnetically levitating “PCI bus” transport layer between them, orchestration as a slurm queue. Andy is not short on analogies.* Why Lila insists it is not an automation company. They optimize for flexibility and generalizability over raw throughput, which means humans stay below the API line wherever automating does not pay.* Your experiment has a runtime. We put Escalante Bio's question to Andy: if science is the token generator, what is the runtime of your data collection? His answer, in short, is that you cannot make the ribosome go faster. Why Lila bets on fast round-over-round iteration rather than big noisy multiplexed screens, and how Rafa's team rebuilt a gas sorption measurement to run roughly 2,500x faster.* What is actually in 10 trillion scientific tokens. Not sequences. Experimentally verified reasoning traces, a kind of data that Andy argues exists on the internet in quantities that round to zero.* Breadth as a path to depth. Small molecule chemistry priors transferring to metal organic frameworks for carbon capture, and the claim that the general model beats domain-specific models sample for sample.* If you have the data, what do you need the model for? Sri Kosuri's koan about the ML-for-drug-discovery business model, and Andy's answer: the coding model got better because it also read Shakespeare and carnitas recipes.* The serendipity they want to automate. Emily Whitehead survived the first pediatric CAR-T cure only because the doctor treating her happened to know, from pediatric arthritis, which antibody would blunt her IL-6 response. Roll that dice again and you probably lose her. Breadth is how you stop depending on luck.* Move 37 for catalysts. Model suggestions for platinum-group-free electrocatalysts that went from boring, to what a 40-paper expert called stupid, to the best performers they have made.* Six months to in vivo CAR-T data in non-human primates, and the zero-FTE virtual startup commercial model that fell out of it. For context on why that number is startling, AbbVie paid $2.1B for Capstan on the strength of preclinical in vivo CAR-T data.* You cannot have scientific superintelligence if you are just a good test taker. Ken Stanley, who wrote Why Greatness Cannot Be Planned, runs open-endedness at Lila. RL at scale gives you a ruthlessly Vulcan problem solver. Machine creativity is a different thing, and it is the part nobody has solved.* The chain of thought is an unreliable narrator. The model reasons in latent space and only emits tokens. Sometimes it skips the experiment entirely and is still right. So how much do you trust the reasoning versus the verifier?* Reward hacking when the rollout is physical. Chains of thought that collapse into repetition, and a model that got annoyed and swore at the scientist who kept asking it to redo a plate map. What happens when a pathological loop has a wet lab inside it?* The bittersweet lesson. Rafa's inversion of the bitter lesson: in AI, scaling is a roadmap. In materials, scaling is a filter, because only the things that scale end up mattering.* Not your typical Flagship company. Why a famously single-asset biotech incubator spun out a platform bet, and Andy's line that if Lila called itself a biopharma it would have a top-three GPU cluster.* Bottlenecks they would remove by fiat. Sim-to-real for physics-based simulation, and the fact that RL training runs at roughly 5% mean FLOP utilization.Watch on YouTube: This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.latent.space/subscribe

Alissa Coram and Ken Shreve walk through Thursday's market action with key stocks to watch in Stock Market Today. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In der heutigen Folge sprechen die Finanzjournalisten Nando Sommerfeldt und Holger Zschäpitz über eine neue Tonlage bei VW, die Folgen der Gesundheitsreform und was sonst noch wichtig wird in dieser Woche. Außerdem geht es um EasyJet, Apollo Global, IAG, Air France-KLM, Brink's, NCR Atleos, T. Rowe Price, Aurora Innovation, FedEx, Volvo, Ascendis Pharma, MoonLake Immunotherapeutics, Dyne Therapeutics, Vaxcyte, Cytokinetics, CG Oncology, Denali Therapeutics, AbbVie, Apogee Therapeutics, Bending Spoons, Mattel, Scotts Miracle-Gro, Goldman Sachs, Bank of America, JPMorgan, Citigroup, Wells Fargo, Morgan Stanley, BlackRock, ASML, TSMC, Netflix, ABB, Abbott, GE Aerospace, Intuitive Surgical, UnitedHealth, Alcoa, United Airlines, BHP, Fraport, Fastenal, Altria, Nvidia, Coca-Cola, Apple, Microsoft, Alphabet, Amazon, Broadcom, Vulcan Materials, Kansas City Southern, IBM, General Dynamics, Hershey, Tootsie Roll, Axon, Tesla, SPDR MSCI ACWI IMI (WKN: A1JJTD), iShares Edge MSCI World Momentum Factor ETF (WKN: A12ATF). Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und – ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Anzeige: Diese Folge enthält Werbung für Smartbroker+. Depot eröffnen, 30 € ETF als Bonus sichern und aus tausenden ETFs wählen. Smartbroker+ macht Investieren einfach. Alle Informationen gibt es unter: https://get.smartbrokerplus.de/triple-aaa-podcast2/ Anzeige: Eight Sleep: Der Pod 5 reguliert die Temperatur im Bett automatisch, trackt Schlaf- und Gesundheitswerte ohne Wearable und kann so zu besserem Schlaf beitragen. Mit dem Code ALLESAUFAKTIEN erhaltet ihr auf https://www.eightsleep.com/allesaufaktien bis zu 350 Euro Rabatt. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

On this re-release 2 Minutes of Motivation episode of the Live Greatly podcast, Kristel Bauer shares three practical steps to take ownership of your happiness. Learn how small shifts in your mindset and daily habits can help you cultivate greater happiness, improve your well-being, and build a more fulfilling life. If you enjoy this episode, be sure to follow the Live Greatly podcast for more short mindset boosts and conversations with world-class leaders, authors, and experts focused on leadership, resilience, well-being, and sustainable high performance. If you're looking to support your team with sustainable high performance, resilience, and clear decision-making in high-pressure environments, Kristel brings these strategies to organizations through engaging keynote experiences. Learn more: www.livegreatly.co  Hosted by Kristel Bauer, keynote speaker, author, and performance expert. Kristel delivers high-impact keynotes on: Peak performance Burnout prevention Leadership development Workplace well-being Sustainable success

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and challenges shaping the landscape of these dynamic sectors. Starting with Ipsen's Dysport, which has made notable strides in its Phase 3 trials for migraine prevention. The trials covered both episodic and chronic conditions, marking a first in the neurotoxin market. Dysport's success positions it as a formidable competitor to AbbVie's Botox, expanding therapeutic options for individuals battling migraine disorders. This achievement showcases the potential efficacy of botulinum toxin-based therapies in neurology and pain management, offering promising new avenues for patient care. In regulatory news, Boehringer Ingelheim has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for Jascayd, a small molecule PDE4B inhibitor with antifibrotic properties. This approval marks a significant milestone in the treatment of idiopathic and progressive pulmonary fibrosis. Jascayd's addition to the therapeutic arsenal offers new hope for managing this debilitating condition, emphasizing the ongoing efforts to improve patient outcomes through innovative treatments. The arena of business development sees HanChorBio partnering with InxMed to advance oncology research. By combining HCB101 with FAK inhibitors and FAP-targeted ADCs, this collaboration aims to leverage antibody and small molecule drug discovery techniques. The goal is to develop innovative cancer treatments that could redefine therapeutic approaches in oncology. Keenova Therapeutics has also reported success with Xiaflex for plantar fibromatosis. This enzyme injection therapy offers a novel approach by targeting collagen, thus providing an innovative solution for musculoskeletal conditions. Similarly, Fate Therapeutics' FT819, an off-the-shelf CAR-T therapy, has shown early promise in tackling treatment-resistant systemic sclerosis, underscoring the potential of cell therapies beyond oncology. Meanwhile, MindRank's successful Series B funding round of $52 million highlights the growing role of AI platforms in drug discovery. The funding will propel its AI-discovered oral GLP-1 obesity pill into Phase III trials, exemplifying how technology-driven solutions are gaining traction in addressing metabolic diseases like obesity. On the regulatory front, Saol Therapeutics has resubmitted SL1009 (DCA) to the FDA for pyruvate dehydrogenase complex deficiency. This submission underscores ongoing efforts to address rare metabolic disorders using small molecule therapies. Additionally, Sanofi's concessions to the EU regarding flu vaccine marketing illustrate the complexities of competitive dynamics and regulatory scrutiny within the vaccine market. However, not all developments are favorable. AstraZeneca and Ionis Pharmaceuticals faced a setback as their drug Wainua failed its Phase 3 trial for transthyretin-mediated amyloid cardiomyopathy. This outcome highlights the challenges inherent in developing effective treatments for complex cardiovascular conditions. Meanwhile, regulatory processes remain contentious as the FDA pauses its release of complete response letters amid debates over proprietary information disclosures. In another noteworthy development, GSK has terminated its $2.2 billion collaboration with Alector after underwhelming results from Alzheimer's drug trials. This decision highlights both financial implications and strategic shifts as companies reassess risk tolerance in neurodegenerative disease research. Conversely, Roche's success with its KRAS G12C inhibitor divarasib in Phase 3 lung cancer trials underscores the promise of precision medicine. Divarasib outperformed competitors Amgen's Lumakras and Bristol Myers Squibb's Krazati, positioning Roche to potentially redefine standards of care based on genetic profiles. In a move reflecting industry trends towards collaboration and innovation risk-sharing models, AstraZeneca has partnered with Sino Biopharmaceutical on respiratory disease research. This strategic alliance represents a substantial investment aimed at expanding AstraZeneca's pipeline in respiratory therapeutics. Lastly, amidst these developments, psychedelic drugs are experiencing a renaissance in psychiatric care. Companies like Compass Pathways are pioneering clinical validation for their use in treating depression, signaling a potential paradigm shift from traditional SSRIs to newer therapeutic classes pending safety and efficacy data. Overall, these stories illustrate a dynamic interplay of scientific progress and regulatory navigation within the pharmaceutical and biotech sectors. While challenges persist—particularly in neurodegenerative disease treatment—the breakthroughs in oncology and metabolic disorder therapeutics offer hopeful prospects for improving patient care. As these industries continue evolving, integrating advanced technologies such as AI will likely play a pivotal role in shaping future therapeutic landscapes.Support the show

This episode covers: Cardiology This Week: A concise summary of recent studies AI & digital solutions in emergency medicine Management of heart failure in cardiac amyloidosis Spotlight: Orthodexia-Platypnoea Syndrome Host: Emer Joyce Guests: Marianna Fontana, Wolf Hautz, Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2551 Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Wolf Hautz and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.  Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guests: Marianna Fontana Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/2551   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of compelling stories that showcase the dynamic nature of this industry. In a landmark development, Vertex Pharmaceuticals has made headlines with its acquisition of Crinetics Pharmaceuticals for a staggering $10 billion. This move marks Vertex's strategic expansion into the endocrine disease sector, a significant shift from its traditional focus on cystic fibrosis. Crinetics' innovative approach to treating rare endocrine disorders will allow Vertex to address unmet needs in this area, highlighting a broader industry trend where mergers and acquisitions serve as key strategies for adapting to the evolving scientific landscape and patient demands. While Vertex makes bold moves, Kalohexis is preparing for a confidential initial public offering (IPO), focusing on treatments based on the melanocortin system for obesity and cancer cachexia. The melanocortin system is crucial in regulating energy homeostasis and inflammation, making it a promising target for therapeutic interventions. This development underscores the growing interest in peptide-based therapies and innovative scientific approaches to address complex metabolic disorders, further emphasizing the industry's shift towards tackling significant health challenges such as obesity. Clinical trials continue to be at the forefront of medical advancements. Compass Pathways has reported promising Phase III trial results for COMP360, its psilocybin-based therapy for treatment-resistant depression. These findings indicate a potential breakthrough in psychedelic therapy, offering new hope for patients who haven't benefited from existing antidepressant treatments. The exploration of psychedelics in mental health treatment represents a paradigm shift that could introduce novel therapeutic options and significantly impact patient care. Turning to regulatory news, AbbVie's Tepkinly (epcoritamab) has received European Commission approval for treating relapsed or refractory follicular lymphoma. This approval is based on robust Phase III data, underscoring the potential of bispecific antibodies as effective cancer therapies. Similarly, PharmaEssentia's Besremi (ropeginterferon alfa-2b) has obtained Health Canada approval for polycythemia vera treatment, highlighting the continued relevance of protein and interferon therapies in managing myeloproliferative neoplasms. In business development news, Novo Nordisk and Vivani Medical have partnered to develop an ultra-long-acting semaglutide implant for chronic weight management. This collaboration showcases advancements in drug delivery systems aimed at improving patient compliance and therapeutic outcomes. Meanwhile, Boehringer Ingelheim's licensing agreement with Prime Vector Technologies involves harnessing viral vectors for cancer vaccine development, emphasizing ongoing efforts to innovate within oncology. Despite these advancements, challenges persist within the industry. Notably, Bristol Myers Squibb's Krazati (adagrasib) failed its Phase III confirmatory trial in metastatic colorectal cancer with KRAS G12C mutations. This outcome highlights the complexities involved in developing targeted cancer therapies and underscores the need for continued innovation and exploration of combination treatments. The financial landscape also reflects strategic adjustments with Regeneron Pharmaceuticals reporting a $127 million charge impacting its earnings due to an in-process research and development expense. Additionally, Novartis is undergoing organizational restructuring with workforce reductions aimed at cost management within large pharmaceutical enterprises. On another front, China's recent approval of the world's first CAR-T therapy for solid tumors marks a significant leap forward from its traditional success in hematological malignancies. This development highlights the potential for CAR-T therapies to address complex challenges posed by solid tumors and could have profound implications for global cancer treatment paradigms. AstraZeneca's partnership with CSPC Pharmaceutical represents another strategic collaboration aimed at co-developing kidney disease drugs, reflecting Western pharmaceutical companies' efforts to leverage Chinese biotechnological capabilities. As companies navigate these complexities through strategic acquisitions, partnerships, and groundbreaking research, their ability to adapt will be crucial in shaping future patient care and therapeutic landscapes. The pharmaceutical and biotech industries remain at the forefront of scientific advancement, continually seeking solutions to complex medical needs while adapting to an ever-evolving global landscape.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The first quarter of 2026 has brought a wave of significant changes and advancements in the industry, marked by crucial regulatory updates, strategic acquisitions, and shifts in the competitive landscape. A pressing issue for many companies is the looming patent cliff for several branded biologics. This situation presents both challenges and opportunities for biosimilars in the U.S. market. The introduction of biosimilars for major products like AbbVie's Humira, Johnson & Johnson's Stelara, and Regeneron/Bayer's Eylea is shifting the narrative from slow adoption to a more competitive biosimilar market landscape. Vertex Pharmaceuticals has achieved a milestone with the FDA expanding the label for its gene therapy Casgevy, now approved for treating children as young as two with sickle cell disease or transfusion-dependent beta thalassemia. This expansion emphasizes the potential of gene therapies to revolutionize treatment options for younger patients suffering from these conditions. In a pivotal development, Novartis announced a significant acquisition of UK biotech Myricx. With an upfront payment of $1.1 billion and potential total value up to $1.5 billion, this acquisition is set to enhance Novartis' antibody-drug conjugate (ADC) pipeline by incorporating Myricx's novel payload technology and NMT inhibitor payloads. This move reflects Novartis' focus on precision oncology by improving ADC efficacy through targeting critical enzymatic pathways involved in tumorigenesis. Amgen faced a setback with a voluntary recall of approximately one million bottles of its heart medication Corlanor due to potential contamination, highlighting the critical importance of maintaining rigorous manufacturing quality control to ensure drug safety. The regulatory landscape continues to evolve, illustrated by Robert F. Kennedy Jr.'s Department of Health and Human Services revoking lingering COVID-19 emergency authorizations. This signals a transition towards post-pandemic normalcy and an evolving focus on pandemic preparedness frameworks. Sanofi's Genzyme unit in Ireland faced criticism after an FDA inspection linked to Altuviiio resulted in a Form 483 notice. This incident underscores ongoing challenges in maintaining compliance with stringent regulatory standards and emphasizes the importance of robust quality assurance mechanisms. Lonza is expanding its capacity for producing ADCs and enhancing its partnership with a large U.S. drugmaker, aligning with industry trends toward outsourcing complex biologics manufacturing amid growing demand for ADCs. Genentech is undergoing restructuring, resulting in 103 layoffs as part of a strategic rethink of its early development group. Despite these changes, Genentech entered a $490 million collaboration focused on breast cancer, demonstrating its commitment to innovation amid organizational shifts. AstraZeneca continued its collaborative efforts by signing a $1.7 billion kidney drug discovery pact with Chinese biotech CSPC Pharmaceutical. This partnership emphasizes AstraZeneca's strategy to leverage global collaborations to accelerate drug discovery and development efforts. Scribe Therapeutics filed for an Initial Public Offering (IPO) to advance its CRISPR-based gene editing technologies targeting cardiovascular diseases at a genetic level, highlighting an ongoing shift toward personalized medicine. Celea Therapeutics raised $180 million in venture funding to advance Deupirfenidone into late-stage clinical trials for Idiopathic Pulmonary Fibrosis (IPF), signaling confidence in its therapeutic potential amid ongoing investment trends targeting rare diseases. The Medicines and Healthcare products Regulatory Agency expanded approval for Novo Nordisk's Wegovy for Metabolic-Associated Steatohepatitis with moderate-to-advanced liver fibrosis. This expansion represents significant progress given MASH's rising prevalence and progression risks. BridgeBio's ATTRibute-CM study yielded promising results with Acoramidis offering kidney-protective benefits in transthyretin amyloidosis cardiomyopathy patients—a potential new approach managing this rare disease. Revolution Medicines reported encouraging data for its KRAS inhibitor Zoldonrasib in combination therapies targeting metastatic pancreatic ductal adenocarcinoma—offering new strategies against aggressive cancer types. Brii Bio's phase 2b trial results show promise for a combination therapy aimed at achieving a functional cure for chronic Hepatitis B Virus infection—offering hope for millions affected by this condition. Robust fundraising activities continue within biotech sectors as Monash University and Atisama Therapeutics secure funding from MRFF grants developing therapies targeting chronic lung diseases. Overall, these developments highlight dynamic transformations reshaping therapeutic landscapes through precision medicine approaches leveraging cutting-edge technologies promising improved patient care across various domains within pharmaceutical industries globally.Support the show

A judge dismissed Edgewater residents' lawsuit to overturn Broadway's rezoning. Crain's commercial real reporter Rachel Herzog talks with host Amy Guth about what's next for the neighborhood. Plus: Developer withdraws rezoning request for controversial Hoffman Estates data center, office building near Fulton Market trades at a major discount, Northwestern plans $275 million facility do-over in Orland Park amid cancer care race and AbbVie faces federal probe over drug trials in China. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this Live Greatly 2 Minutes of Motivation podcast episode, Kristel Bauer shares 3 practical strategies to help you navigate high-pressure situations with greater confidence and resilience. Learn how to manage your attention when nerves, fear, and self-doubt arise so you can perform at your best. Tune in now! If you enjoy this episode, be sure to follow the Live Greatly podcast for more short mindset boosts and conversations with world-class leaders, authors, and experts focused on leadership, resilience, well-being, and sustainable high performance. If you're looking to support your team with sustainable high performance, resilience, and clear decision-making in high-pressure environments, Kristel brings these strategies to organizations through engaging keynote experiences. Learn more: www.livegreatly.co  Hosted by Kristel Bauer, keynote speaker, author, and performance expert. Kristel delivers high-impact keynotes on: Peak performance Burnout prevention Leadership development Workplace well-being Sustainable success

Greg Doggett, Counsel, Powers Pyles Sutter & Verville PC, and Felicity Homsted, CEO, FQHC 340B Compliance, discuss the current legal and regulatory landscape of the 340B program. They cover the intersection of 340B with the Inflation Reduction Act, concerns about the Rebate Model, pharmaceutical manufacturer restrictions and data requirements for covered entities, AbbVie's patient definition lawsuit, state reporting requirements, and potential Congressional action.Watch this episode: https://www.youtube.com/watch?v=KsnP7hLbvekEssential Legal Updates, Now in AudioAHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Comprehensive members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast.Stay At the Forefront of Health Legal EducationLearn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/. 

How Targeted Therapies Are Reshaping Treatment for Platinum-Resistant Ovarian Cancer Platinum-resistant ovarian cancer remains one of the most challenging settings in oncology, with limited treatment options and historically poor outcomes for many patients. On this episode of Unscripted, the AMCP Podcast, guest host Abby Kim, PharmD, BCOP, Senior Director of Clinical Strategy and Oncology Specialty Solutions at Prime Therapeutics, sits down with Kathleen Moore, MD, Deputy Director of the Fred & Pamela Buffett Cancer Center and Professor of Obstetrics and Gynecology at Nebraska Medicine, to discuss the evolving treatment landscape for recurrent ovarian cancer and the growing role of biomarker-driven care. Dr. Moore explores the history and challenges of treating platinum-resistant disease, reviews the clinical evidence behind ELAHERE®, examines the importance of folate receptor alpha testing, and shares insights on treatment sequencing, patient-reported outcomes, safety and tolerability considerations, and emerging therapies that may further expand options for patients and inform decision-making across managed care. Sponsored by Abbvie, Inc. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant advancements and strategic shifts reshaping the industry landscape. To begin, the U.S. Food and Drug Administration has taken a noteworthy step by selecting key industry players, including Eli Lilly, Regeneron, Fujifilm, and Kriya Therapeutics, for its PreCheck pilot program. This initiative is designed to enhance U.S. drug manufacturing capabilities, emphasizing the importance of robust domestic production. By reducing dependency on international supply chains, the program aims to expedite the delivery of critical therapies, highlighting a strategic move towards self-reliance in pharmaceutical manufacturing. In oncology news, Beone's Brukinsa (zanubrutinib), a small molecule BTK inhibitor, has demonstrated a remarkable 43% reduction in risk of progression for patients with first-line mantle cell lymphoma in its Phase 3 trial. This breakthrough offers a promising chemotherapy-free option for non-Hodgkin lymphoma treatment, marking significant progress in targeted cancer therapies that could improve patient outcomes in previously underserved areas. Meanwhile, Boulevard Bio and Metis TechBio have sealed a substantial licensing agreement valued at $1.6 billion for MTS-128, a trispecific T-cell engager aimed at autoimmune diseases. This collaboration reflects a broader industry trend towards leveraging advanced AI and machine learning technologies to enhance the development of precision medicine and personalized therapies. Such partnerships indicate a shift towards more innovative approaches to tackling complex disease mechanisms and illustrate burgeoning interest in multispecific biologics within immunotherapy domains—offering new avenues for targeting multiple disease pathways simultaneously. On the regulatory front, Sanofi is advancing efforts to expand the U.S. label for Nexviazyme (avalglucosidase alfa) following successful Phase 3 trials for infantile-onset Pompe disease. As an enzyme replacement therapy targeting GAA enzyme deficiency, Nexviazyme could address a critical gap in treatment options for this debilitating genetic disorder, underlining the importance of regulatory pathways in facilitating access to life-saving therapies. Financially, Beeline Medicines has garnered $126.3 million in Series A extension funding to propel its autoimmune programs originally sourced from Bristol Myers Squibb. Similarly, SmartBax has raised €6.3 million to advance its lead antibiotic program targeting multi-drug resistant infections. These investments underscore an unwavering focus on addressing unmet medical needs through innovative therapeutic solutions. Regulatory challenges persist as well; Unicycive Therapeutics faced FDA rejection due to third-party manufacturing deficiencies surrounding oxylanthanum carbonate. This setback emphasizes the critical importance of maintaining rigorous quality standards throughout drug production processes to secure regulatory approvals and ensure patient safety. Globally, China has achieved a milestone with the approval of the world's first CAR-T therapy for solid tumors—a significant leap forward given the historical challenges of applying CAR-T technology beyond hematological malignancies. This approval could transform cancer treatment paradigms globally and prompt similar regulatory advancements in other regions. In other developments, Abbvie and Genmab's combination therapy involving Epkinly has shown promise in diffuse large B-cell lymphoma (DLBCL) trials following prior challenges with monotherapy approaches. This success story highlights the potential of combination therapies in enhancing outcomes for patients battling complex cancers like DLBCL. From a corporate perspective, Klick Health's acquisition of Oxford Pharmagenesis marks its third purchase in 18 months, expanding its global footprint and scientific capabilities—a testament to ongoing consolidation trends aimed at augmenting expertise and strategic growth within the sector. These developments collectively paint a picture of an industry dynamically evolving amidst scientific breakthroughs and regulatory recalibrations. As companies navigate this transformative landscape, their ability to adapt and innovate remains paramount for sustaining growth and addressing global healthcare challenges effectively. Stakeholders must remain agile to seize opportunities while mitigating inherent risks in this high-stakes environment that increasingly prioritizes patient-centric innovations.Support the show

On this podcast episode, we spotlight our IPhO Annual Meeting Premier Sponsor, the USC Mann Pharmaceutical Industry Fellowship Program. We are joined by Michael Lim, USC Fellowship Director; along with former fellows Keya Patel, who transitioned from Gilead's Global Medical Affairs HIV Prevention Fellowship to a Global Medical Affairs strategy role in HIV Treatment; and Trey Graham, who transitioned from AbbVie's Medical Affairs Evidence Planning and Execution Fellowship to a Dermatology Medical Science Liaison role. Michael, Keya, and Trey discuss the USC fellowship experience, highlighting the program's supportive structure, professional development opportunities, and resources that help fellows successfully transition into full-time roles. They also share practical advice on taking initiative, setting expectations with preceptors, building meaningful professional relationships, and maximizing the fellowship experience.  Whether you're just starting pharmacy school, finishing your fellowship, or preparing to launch your career, this episode is packed with insights you won't want to miss!

With scores of pending lawsuits involving drugmaker and covered entity challenges of how federal and state governments regulate 340B, the courts have become an important arena in the national 340B debate. 340B Health's Vice President of Legal and Policy Amanda Nagrotsky unpacks some of the cases and what they might mean for 340B's future.Courts Wrestle With Issues of Federal and State AuthorityDrug companies have filed about 80 lawsuits challenging state contract pharmacy protection laws. Nagrotsky says drugmakers are arguing these state laws conflict with federal oversight, but most courts so far have ruled that contract pharmacy protection laws fall within a state's ability to regulate drug distribution and delivery. A recent decision from a federal judge in Mississippi was a major win for covered entities because it completely dismissed a drugmaker's challenge to the state's law rather than just ruling on whether to pause enforcement of the law. AbbVie Challenges 340B Patient DefinitionDrugmaker AbbVie is suing the Health Resources & Services Administration (HRSA) directly, arguing that the definition of whom the agency considers a 340B-eligible patient is too broad. AbbVie's own, narrower patient definition would require drug companies to discount far fewer drugs and thus would limit hospital access to 340B savings significantly. The government is asking the court to dismiss the lawsuit on procedural grounds, and 340B Health along with two member hospitals are asking the court to allow them to intervene as defendants and provide additional arguments for why it should throw out the case.Uncertainty Remains Despite GPO, Child Site RulingsFederal district court decisions found that HRSA failed to explain why it adopted a 2013 policy barring certain 340B hospitals' use of group purchasing organizations (GPOs) to make initial purchases for their virtual inventory systems and a 1994 policy establishing registration prerequisites for new 340B hospital outpatient facilities. Although the government opted against appealing the ruling striking down the GPO policy, the underlying prohibition remains in effect, leaving hospitals in limbo as to how HRSA will interpret the law. The government has appealed the child site ruling, and a final decision on that case will have a major impact on how quickly hospitals can use 340B drugs at new child sites.

In this re-release Live Greatly: 2 Minutes of Motivation episode, Kristel Bauer shares two powerful strategies to help you become a more effective communicator. Whether you're leading a team, navigating challenging conversations, or looking to strengthen your personal and professional relationships, these practical insights can help you communicate with greater impact and connection. Tune in now! If you enjoy this episode, be sure to follow the Live Greatly podcast for more short mindset boosts and conversations with world-class leaders, authors, and experts focused on leadership, resilience, well-being, and sustainable high performance. If you're looking to support your team with sustainable high performance, resilience, and clear decision-making in high-pressure environments, Kristel brings these strategies to organizations through engaging keynote experiences. Learn more: www.livegreatly.co  Hosted by Kristel Bauer, keynote speaker, author, and performance expert. Kristel delivers high-impact keynotes on: Peak performance Burnout prevention Leadership development Workplace well-being Sustainable success

This episode covers: Cardiology This Week: A concise summary of recent studies Host: Emer Joyce Guests: Yasmina Bououdina, JP Carpenter, Milton Packer, Lorenz Raeber Want to watch that episode? Go to: https://esc365.escardio.org/event/2558 Want to watch that extended interview on PCI guidance by intracoronary imaging, go to: https://esc365.escardio.org/event/2558?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Milton Packer has declared to have potential conflicts of interest to report: 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Daiichi Sankyo, Imara, Lilly, Medtronic, Moderna, Novartis, NovoNordisk, Pharmacocosmos, Regeneron, Roche, Salamandra. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Lorenz Raeber has declared to have potential conflicts of interest to report: consultation/speaker fees from Abbott, Boston Scientific, Occlutech, and research grants to the institution by Abbott, Heartflow, Novo Nordisk and Heartflow. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guest: Lorenz Raeber Want to watch that extended interview on https://esc365.escardio.org/event/2558?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2558   Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Lorenz Raeber has declared to have potential conflicts of interest to report: consultation/speaker fees from Abbott, Boston Scientific, Occlutech, and research grants to the institution by Abbott, Heartflow, Novo Nordisk and Heartflow. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Peter Holsten is selling a 17-building portfolio and the firm as he prepares for retirement. Crain's commercial real estate reporter Rachel Herzog discusses with host Amy Guth. Plus: Pritzker wants legislators to take up data centers in the fall, AbbVie to buy immunology drugmaker Apogee for close to $11 billion, Gracias' Valor to raise $2.5 billion fund amid SpaceX backing and Chicago Fed's Goolsbee says too-high inflation is "going the wrong way." Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

AbbVie's $10.9 billion deal to acquire Apogee will expand its immunology pipeline by delivering assets for atopic dermatitis and asthma. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the takeout and the assets AbbVie gains.The analysts then discuss moves by FDA to reverse controversial setbacks that occurred under the agency's former leadership and assess Acting CDER Director Michael Davis' memo outlining how his predecessor repeatedly overruled career staff to quash a drug approval. The analysts also discuss continuing signs of political involvement at FDA.Finally, they discuss China NMPA's first-ever approval of a CAR T for solid tumors, satricabtagene autoleucel (satri-cel) from Carsgen.View full story: https://www.biocentury.com/article/659864#BiotechMA #Immunology #FDA #CART #ChinaBiotech00:59 - AbbVie Buys Apogee05:20 - uniQure U-turn09:02 - FDA Reversals12:32 - Tzield Memo20:53 - Solid Tumor CAR T ApprovalTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Plus: Apogee shares shoot higher as the pharmaceutical giant AbbVie agrees to buy the biotech company for about $10.9 billion. Shares of Intel and Micron climb amid memory-chip shortage. Alexis Green hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Learn more about your ad choices. Visit megaphone.fm/adchoices

Carl Quintanilla, David Faber and Sara Eisen led off the show with market reaction to positive comments by Vice President Vance about the U.S.-Iran negotiations. AI in the spotlight: Chevron announced it signed a 20-year agreement with Microsoft to provide power for the tech giant's massive West Texas data center project. The anchors remembered the influential former Fed chairman Alan Greenspan, who died Monday at the age of 100. Also in focus: President Trump's comments on Anthropic and national security, Microsoft CEO Satya Nadella's message for companies leading the AI boom, SpaceX shares on track for a three-day losing streak, AbbVie agrees to buy immunology drugmaker Apogee Therapeutics for $10.9 billion in cash. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Whiplash hits geopolitical headwinds as a back-and-forth in U.S. and Iran talks fluctuate the price action in futures. Tom White explains why investors should take headlines out of Iran "with a grain of salt" as peace talks to fully reopen the Strait of Hormuz continue. In equities, Tom talks about the price target hikes in AI semiconductor equipment makers and AbbVie's (ABBV) $10.9 billion acquisition of Apogee Therapeutics (APGE). He also touches on reports of SpaceX (SPCX) preparing a $20 billion offering. ======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Want to become a better leader? Start by leading yourself well. In this re-release 2 Minutes of Motivation Live Greatly episode, Kristel Bauer shares an often-overlooked leadership strategy: investing in your own well-being. When you prioritize your physical, mental, and emotional health, you're better equipped to show up for your team, make thoughtful decisions, and lead with intention. Small investments in yourself can have a powerful ripple effect on those around you. Interested in bringing these types of strategies to your organization? Learn more about Kristel Bauer's keynotes and workshops at livegreatly.co. If you enjoy this episode, be sure to follow the Live Greatly podcast for more short mindset boosts and conversations with world-class leaders, authors, and experts focused on leadership, resilience, well-being, and sustainable high performance. If you're looking to support your team with sustainable high performance, resilience, and clear decision-making in high-pressure environments, Kristel brings these strategies to organizations through engaging keynote experiences. Learn more: www.livegreatly.co  Hosted by Kristel Bauer, keynote speaker, author, and performance expert. Kristel delivers high-impact keynotes on: Peak performance Burnout prevention Leadership development Workplace well-being Sustainable success

In this episode of 2 Minutes of Motivation, Kristel Bauer shares 3 powerful self-leadership strategies to help you lead more intentionally and sustainably — both at work and in life. Kristel discusses: Why identifying your non-negotiables matters The importance of creating intentional reset moments throughout the day How being intentional with your relationships can positively impact leadership, culture and fulfillment This short episode is designed to help you reset, refocus and lead yourself with greater intention — especially during demanding seasons. Interested in bringing these types of strategies to your organization? Learn more about Kristel Bauer's keynotes and workshops at livegreatly.co. If you enjoy this episode, be sure to follow the Live Greatly podcast for more short mindset boosts and conversations with world-class leaders, authors, and experts focused on leadership, resilience, well-being, and sustainable high performance. If you're looking to support your team with sustainable high performance, resilience, and clear decision-making in high-pressure environments, Kristel brings these strategies to organizations through engaging keynote experiences. Learn more: www.livegreatly.co  Hosted by Kristel Bauer, keynote speaker, author, and performance expert. Kristel delivers high-impact keynotes on: Peak performance Burnout prevention Leadership development Workplace well-being Sustainable success